Incyte has started a Phase III clinical trial of ruxolitinib (Jakafi) to treat cytokine storm caused by Covid-19 coronavirus infection.
The global, randomised, double-blind, placebo-controlled Phase III trial, named RUXCOVID, will assess the safety and efficacy of ruxolitinib given along with standard-of-care (SoC) in around 400 patients aged ≥12 years worldwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
RUXCOVID is funded by Incyte in the US and Novartis outside of the US. Earlier this month, Incyte and Novartis announced plans to conduct the Phase III trial.
